Mirae Asset Global Investments Co. Ltd. Trims Stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Mirae Asset Global Investments Co. Ltd. cut its stake in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 19.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 11,129 shares of the company’s stock after selling 2,685 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in iTeos Therapeutics were worth $122,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Bank of New York Mellon Corp increased its stake in shares of iTeos Therapeutics by 6.5% in the third quarter. Bank of New York Mellon Corp now owns 278,959 shares of the company’s stock worth $3,055,000 after purchasing an additional 17,090 shares in the last quarter. Panagora Asset Management Inc. raised its holdings in iTeos Therapeutics by 20.9% during the third quarter. Panagora Asset Management Inc. now owns 146,276 shares of the company’s stock valued at $1,602,000 after acquiring an additional 25,237 shares during the period. Principal Financial Group Inc. lifted its position in shares of iTeos Therapeutics by 3.8% in the third quarter. Principal Financial Group Inc. now owns 152,342 shares of the company’s stock valued at $1,668,000 after acquiring an additional 5,555 shares in the last quarter. Syon Capital LLC bought a new position in shares of iTeos Therapeutics in the third quarter worth about $135,000. Finally, Barclays PLC grew its position in shares of iTeos Therapeutics by 2.4% during the third quarter. Barclays PLC now owns 322,322 shares of the company’s stock worth $3,529,000 after purchasing an additional 7,442 shares in the last quarter. Institutional investors own 97.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on ITOS shares. Wedbush restated an “outperform” rating and issued a $18.00 price target (down from $25.00) on shares of iTeos Therapeutics in a research note on Wednesday, March 6th. HC Wainwright restated a “buy” rating and set a $44.00 target price on shares of iTeos Therapeutics in a research report on Thursday, March 7th.

iTeos Therapeutics Price Performance

NASDAQ ITOS opened at $10.80 on Monday. The stock has a market capitalization of $387.07 million, a PE ratio of -3.43 and a beta of 1.19. iTeos Therapeutics, Inc. has a 1-year low of $8.20 and a 1-year high of $18.24. The business has a 50 day simple moving average of $11.45 and a two-hundred day simple moving average of $10.62.

iTeos Therapeutics (NASDAQ:ITOS) last announced its quarterly earnings results on Wednesday, March 6th. The company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($1.03) by $0.18. On average, analysts anticipate that iTeos Therapeutics, Inc. will post -4.76 EPS for the current fiscal year.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.